Evolution of the Average Target: Viking Therapeutics, Inc.

Evolution of the Target Price: Viking Therapeutics, Inc.

Changes in Analyst Recommendations: Viking Therapeutics, Inc.

af996a3745718318a1648f7016ab8ad5.H0t4GKS_Q6uCLXx5laIz0gLYx75F0mE4CrrHnsSUInk.ej4PSfPPJ_3DdBZU1tBklGSqiosLlVMPT4mLyZCjehVbLwlI1oom_9pqMQ~b3635523ad1500c38cb20d9babdc7d6d
08-03 Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says MT
05-28 Lake Street Initiates Viking Therapeutics With Buy Rating, $89 Price Target MT
04-30 Viking Therapeutics Q1 Viewed as Supporting Maintenance Profile, Oppenheimer Says MT
04-08 Viking Therapeutics May Benefit From New Era for Weight Loss Pills, Oppenheimer Says MT
02-12 Morgan Stanley Trims Price Target on Viking Therapeutics to $99 From $102, Keeps Overweight Rating MT
11-06 Viking Therapeutics highlights clinical data from VK2735 obesity program in presentation at ObesityWeek 2025 RE
25-10-29 Canaccord Genuity Initiates Viking Therapeutics at Buy With $106 Price Target MT
25-10-23 Morgan Stanley Raises Price Target on Viking Therapeutics to $102 From $98, Keeps Overweight Rating MT
25-10-22 Viking Therapeutics misses Q3 profit estimates RE
25-08-19 Viking Therapeutics' Share Sell-Off After Obesity Drug Data 'Overreaction,' Truist Says MT
25-04-29 Cantor Fitzgerald Initiates Viking Therapeutics at Overweight With $104 Price Target MT
25-04-25 Truist Securities Cuts Viking Therapeutics Price Target to $75 From $95, Maintains Buy Rating MT
25-04-24 B. Riley Adjusts Price Target on Viking Therapeutics to $85 From $96, Maintains Buy Rating MT
25-04-23 Oppenheimer Cuts Price Target on Viking Therapeutics to $100 From $164, Keeps Outperform Rating MT
25-04-08 Goldman Sachs Initiates Viking Therapeutics With Neutral Rating, $30 Price Target MT
25-02-13 Scotiabank Initiates Viking Therapeutics at Sector Outperform MT
25-02-07 B. Riley Adjusts Price Target on Viking Therapeutics to $96 From $109, Keeps Buy Rating MT
25-02-07 Citigroup Initiates Viking Therapeutics at Neutral With $38 Price Target MT
25-02-07 Truist Securities Adjusts Viking Therapeutics Price Target to $95 From $120, Maintains Buy Rating MT
24-12-02 Piper Sandler Initiates Viking Therapeutics at Overweight MT
24-11-22 B. Riley Initiates Viking Therapeutics at Buy With $109 Price Target MT
24-11-04 Oppenheimer Adjusts Viking Therapeutics Price Target to $164 From $138, Maintains Outperform Rating MT
24-09-11 JPMorgan Initiates Viking Therapeutics at Overweight With $80 Price Target MT
24-06-27 Morgan Stanley Initiates Viking Therapeutics at Overweight With $105 Price Target MT
24-05-17 Raymond James Upgrades Viking Therapeutics to Strong Buy From Outperform MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+14.62%
- +7.51%
+7.74%
+6.28%
+60.93%
+11.65%
-15.34%
+18.07%
-5.53%
Average +11.77%
Weighted average by Cap. +12.80%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
34.38USD
Average target price
92.39USD
Spread / Average Target
+168.75%
High Price Target
125.00USD
Spread / Highest target
+263.58%
Low Price Target
35.00USD
Spread / Lowest Target
+1.80%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. VKTX Stock
  4. 1VT Stock
  5. Consensus Viking Therapeutics, Inc.